TY - JOUR T1 - Review: atenolol may be ineffective for reducing cardiovascular morbidity or all cause mortality in hypertension JF - Evidence Based Medicine JO - Evid Based Med SP - 74 LP - 74 DO - 10.1136/ebm.10.3.74 VL - 10 IS - 3 A2 - , Y1 - 2005/06/01 UR - http://ebm.bmj.com/content/10/3/74.abstract N2 - Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684–9.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with essential hypertension, does atenolol reduce cardiovascular morbidity or all cause mortality? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Cardiology ★★★★★☆☆ Data sources: Cochrane Library, Medline, relevant textbooks, and researchers in hypertension. Study selection and assessment: randomised controlled trials (RCTs) that assessed the effect of atenolol (as the sole first line drug in 1 of the treatment groups) on cardiovascular morbidity or mortality in patients with essential hypertension. Outcomes: myocardial infarction (MI), stroke, cardiovascular mortality, and all cause mortality. 8 RCTs met the selection criteria. 2 major comparisons were made. Atenonol compared with placebo or with untreated controls (4 RCTs, n = 6825). Mean reduction in blood pressure (BP) … ER -